6505--FY27 Lenalidomide BPA
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
262-NETWORK CONTRACT OFFICE 22 (36C262)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36C26227Q0083
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents1
The Department of Veterans Affairs (VA), through its Network Contract Office 22, has issued a Sources Sought Notice (Procurement Identifier: 36C26227Q0083) to gather information from qualified vendors capable of supplying Lenalidomide medication under a prospective Blanket Purchase Agreement (BPA) for Fiscal Year 2027. This Request for Information (RFI) is intended solely for market research and planning purposes and does not constitute a solicitation or a commitment to contract.
Purpose and Scope:
The primary objective of this procurement is to establish a BPA for the supply and delivery of Lenalidomide, an oral immunomodulatory medication used in the treatment of various blood cancers, to multiple VA Medical Centers (VAMCs) within Health Service Area (HSA) 5.3. The agreement will cover the provision of Lenalidomide in six dosage strengths (2.5mg, 5mg, 10mg, 15mg, 20mg, and 25mg capsules) to support the ongoing clinical needs of veterans at the following participating VAMCs:
- VA Albuquerque Healthcare System (NM)
- VA Long Beach Healthcare System (CA)
- VA Loma Linda Healthcare System (CA)
- VA Phoenix Healthcare System (AZ)
- VA Prescott Healthcare System (AZ)
- VA San Diego Healthcare System (CA)
- VA Tucson Healthcare System (AZ)
- VA Greater Los Angeles Healthcare System (CA)
The estimated number of patients per facility for FY26 ranges from 13 to 32, based on historical data. However, the VA does not guarantee specific quantities, as actual requirements will depend on individual patient needs and provider decisions. Orders will be placed as needed by each station, and the contractor will be compensated only for quantities delivered and accepted.
Key Requirements and Deliverables:
- The contractor must be certified under the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program for Lenalidomide dispensing.
- The contractor is responsible for the timely delivery of medication to each specified VAMC, ensuring compliance with all handling, storage, and transportation requirements to maintain product integrity.
- Pricing must be provided for all dosage strengths, with orders placed via approved purchase orders signed by warranted Contracting Officers.
- Payment will be processed upon delivery and acceptance by each medical center, using the Tungsten network for invoicing.
- The period of performance for the BPA is anticipated to be one year from the date of award.
Contracting Entity and Classification:
- Contracting Entity: 262-Network Contract Office 22 (36C262), Department of Veterans Affairs
- NAICS Code: 325412 (Pharmaceutical Preparation Manufacturing), size standard 1,300 employees
- Product Service Code: 6505 (Drugs and Biologicals)
- Primary Contact: Hestia Sim ([email protected])
Procurement Type and Special Considerations:
This notice is a Sources Sought/RFI and not a solicitation. The VA is seeking information from all business sizes and classifications, including Service-Disabled Veteran-Owned Small Businesses (SDVOSB), Veteran-Owned Small Businesses (VOSB), HUBZone, Woman-Owned Small Businesses (WOSB), and large businesses. Respondents are encouraged to provide detailed capability statements addressing their ability to meet the requirements, business size status, distribution capabilities, compliance with the Non-Manufacturer Rule, Buy American Act, and other relevant federal regulations.
Additional Considerations:
- The contractor must confirm REMS certification and FDA clearance for Lenalidomide.
- Vendors should indicate whether the products are Commercial Off-The-Shelf (COTS) items and provide information on lead times, product lifespan, support services, and any available federal supply schedules or contracts.
- The VA is also interested in feedback regarding the Statement of Work (SOW) and suggestions for improving the procurement process.
Submission Instructions:
Interested parties must submit responses via email to Hestia Sim at [email protected] by 10:00 AM Pacific Time on November 12, 2026. Responses should include company information, capabilities, business size, and answers to the specific questions outlined in the notice. All information provided will be used for planning purposes only and will not be considered as offers or proposals for contract award.
This opportunity is particularly relevant for pharmaceutical manufacturers and authorized distributors with experience in supplying specialty medications to federal healthcare facilities, and who can demonstrate compliance with stringent regulatory and quality requirements. Contractors should carefully review the requirements and ensure their capabilities align with the VA’s needs for reliable, compliant, and timely delivery of Lenalidomide to multiple locations.
For further details and to access the official notice, visit: https://sam.gov/opp/d13b067a4252475d95d1ebb22b7c1ae5/view